Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Brock, Susannah"'
Autor:
James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gert, Brawley, Chris D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., Bono, Johann S., Montana, Carlos Diaz, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominic R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W.S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob, Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K.B., Sydes, Matthew R.
Publikováno v:
James, N D, Clarke, N W, Cook, A, Ali, A, Hoyle, A P, Attard, G, Brawley, C D, Chowdhury, S, Cross, W R, Dearnaley, D P, Bono, J S, Montana, C D, Gilbert, D, Gillessen, S, Gilson, C, Jones, R J, Langley, R E, Malik, Z I, Matheson, D J, Millman, R, Parker, C C, Pugh, C, Rush, H, Russell, J M, Berthold, D R, Buckner, M L, Mason, M D, Ritchie, A WS, Birtle, A J, Brock, S J, Das, P, Ford, D, Gale, J, Grant, W, Gray, E K, Hoskin, P, Khan, M M, Manetta, C, McPhail, N J, O'Sullivan, J M, Parikh, O, Perna, C, Pezaro, C J, Protheroe, A S, Robinson, A J, Rudman, S M, Sheehan, D J, Srihari, N N, Syndikus, I, Tanguay, J, Thomas, C W, Vengalil, S, Wagstaff, J, Wylie, J P, Parmar, M KB & Sydes, M R 2022, ' Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476) ', International Journal of Cancer . https://doi.org/10.1002/ijc.34018
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multi-arm, multi-stage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d41e4f972431efac3e44597e81d1a4a
https://pure.qub.ac.uk/en/publications/3adddebe-1d1a-4134-8495-5f087a1fee9e
https://pure.qub.ac.uk/en/publications/3adddebe-1d1a-4134-8495-5f087a1fee9e
Autor:
Cook, Audrey, Beesley, Sharon, O'Sullivan, Joe M, Birtle, Alison J, Thalmann, George, Graham, John D, Spears, Melissa R, Brock, Susannah, Srinivasan, Rajaguru, Protheroe, Andrew, Sydes, Matthew R, Laing, Robert, Cross, William, Matheson, David, Tsang, David, Parmar, Mahesh K B, Sundar, Santhanam, McKinna, Fiona, Parikh, Omi, Chowdhury, Simon, Robinson, Angus J, De Bono, Johann, Elliott, Tony, Mason, Malcolm D, Parker, Christopher C, Alzouebi, Mymoona, Gibbs, Stephanie, Dearnaley, David P, Millman, Robin, Russell, J Martin, Tolan, Shaun, Chakraborti, Prabir, Cathomas, Richard, Srihari, Narayanan, Clarke, Noel W, Peedell, Clive, James, Nicholas D, Staffurth, John, Gale, Joanna, Hetherington, John, Amos, Claire, Attard, Gerhardt, Hughes, Robert, Jones, Rob J, Ritchie, Alastair W S, McLaren, Duncan B, Wagstaff, John
Publikováno v:
James, N D, Sydes, M R, Clarke, N W, Mason, M D, Dearnaley, D P, Spears, M R, Ritchie, A W S, Parker, C C, Russell, J M, Attard, G, de Bono, J, Cross, W, Jones, R J, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, J D, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, D B, O'Sullivan, J M, Parikh, O, Peedell, C, Protheroe, A, Robinson, A J, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, Parmar, M K B & STAMPEDE investigators 2016, ' Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial ', Lancet, vol. 387, no. 10024, pp. 1163–1177 . https://doi.org/10.1016/S0140-6736(15)01037-5
Lancet (London, England), vol. 387, no. 10024, pp. 1163-1177
Lancet, vol. 387, no. 10024, pp. 1163-1177
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5
Lancet (London, England), vol. 387, no. 10024, pp. 1163-1177
Lancet, vol. 387, no. 10024, pp. 1163-1177
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5
BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced